Vorinostat Completed Phase 2 Trials for Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00720876Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma